These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 8714617)

  • 61. Two New Drugs Approved for Multiple Sclerosis.
    Aschenbrenner DS
    Am J Nurs; 2019 Jul; 119(7):22-23. PubMed ID: 31232771
    [No Abstract]   [Full Text] [Related]  

  • 62. [2-chlorodeoxyadenosine (2-CDA)--a new antineoplastic and immunosuppressive drug].
    Robak T; Grieb P
    Acta Haematol Pol; 1992; 23(3):141-8. PubMed ID: 1362851
    [No Abstract]   [Full Text] [Related]  

  • 63. High-dose dexamethasone therapy for resistant autoimmune thrombocytopenic purpura.
    Godeau B; Bierling P; Oksenhendler E; Castaigne S; Deconinck E; Wechsler B
    Am J Hematol; 1996 Apr; 51(4):334. PubMed ID: 8602642
    [No Abstract]   [Full Text] [Related]  

  • 64. Influence of the new medicine--2-CDA (Cladribine) on the ultrastructure of the extrabulbar segment of the optic nerve in rabbits of New Zealand breed.
    Kwietniewska M; Stelmasiak Z; Sekita-Krzak J; Visconti J; Czerny K
    Ann Univ Mariae Curie Sklodowska Med; 2002; 57(2):227-32. PubMed ID: 12898844
    [TBL] [Abstract][Full Text] [Related]  

  • 65. [Long-term effects of glatiramer acetate in multiple sclerosis].
    Brochet B
    Rev Neurol (Paris); 2008 Nov; 164(11):917-26. PubMed ID: 18790510
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Development of progressive multifocal leukoencephalopathy in a patient with non-Hodgkin lymphoma 13 years after treatment with cladribine.
    Berghoff M; Schänzer A; Hildebrandt GC; Dassinger B; Klappstein G; Kaps M; Gizewski ER; Acker T; Grams A
    Leuk Lymphoma; 2013 Jun; 54(6):1340-2. PubMed ID: 23098217
    [No Abstract]   [Full Text] [Related]  

  • 67. Copolymer 1 from the laboratory to FDA.
    Teitelbaum D; Sela M; Arnon R
    Isr J Med Sci; 1997 Apr; 33(4):280-4. PubMed ID: 9347880
    [No Abstract]   [Full Text] [Related]  

  • 68. Adverse and beneficial immunological effects of purine nucleoside analogues.
    Dighiero G
    Hematol Cell Ther; 1996 Dec; 38 Suppl 2():S75-81. PubMed ID: 9137960
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Autologous stem-cell transplantation in malignant multiple sclerosis: a case with a favorable long-term outcome.
    Kimiskidis V; Sakellari I; Tsimourtou V; Kapina V; Papagiannopoulos S; Kazis D; Vlaikidis N; Anagnostopoulos A; Fassas A
    Mult Scler; 2008 Mar; 14(2):278-83. PubMed ID: 17942513
    [TBL] [Abstract][Full Text] [Related]  

  • 70. [Immunosuppressive agents in multiple sclerosis. Preliminary trials with Proresid].
    Danielczyk W
    Wien Med Wochenschr; 1968 Nov; 118(44):934-7. PubMed ID: 5710171
    [No Abstract]   [Full Text] [Related]  

  • 71. The value of magnetic resonance imaging in diagnosis and monitoring of treatment in multiple sclerosis.
    Bekiesińska-Figatowska M; Walecki J; Stelmasiak Z
    Acta Neurobiol Exp (Wars); 1996; 56(1):171-6. PubMed ID: 8787171
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Therapeutic trials for multiple sclerosis.
    McKhann GM
    Ann Neurol; 1990 Jun; 27(6):589-90. PubMed ID: 2193612
    [No Abstract]   [Full Text] [Related]  

  • 73. [Immunosuppressive mechanisms for immunoglobulin function].
    Miller A; Jedrzejczak WW
    Postepy Hig Med Dosw; 2000; 54(4):423-44. PubMed ID: 11016265
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Management of worsening multiple sclerosis with mitoxantrone: a review.
    Fox EJ
    Clin Ther; 2006 Apr; 28(4):461-74. PubMed ID: 16750460
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Multiple sclerosis: Prospects and promise.
    Hauser SL; Chan JR; Oksenberg JR
    Ann Neurol; 2013 Sep; 74(3):317-27. PubMed ID: 23955638
    [TBL] [Abstract][Full Text] [Related]  

  • 76. [Various aspects of immunopathogenesis of multiple sclerosis and therapeutic possibilities].
    Aleksandrowicz J; Blicharski J; Skotnicki A; Retinger M; Zduńczyk A
    Pol Tyg Lek; 1981 Aug; 36(35):1363-5. PubMed ID: 7036112
    [No Abstract]   [Full Text] [Related]  

  • 77. New treatment options for immune-mediated hematological disorders.
    Dierickx D; De Rycke A; Vanderschueren S; Delannoy A
    Eur J Intern Med; 2008 Dec; 19(8):579-86. PubMed ID: 19046722
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Treatment of multiple sclerosis with the pregnancy hormone estriol.
    Sicotte NL; Liva SM; Klutch R; Pfeiffer P; Bouvier S; Odesa S; Wu TC; Voskuhl RR
    Ann Neurol; 2002 Oct; 52(4):421-8. PubMed ID: 12325070
    [TBL] [Abstract][Full Text] [Related]  

  • 79. [Cladribin. Development of an oral formulation for the treatment of multiple sclerosis].
    Hartung HP; Kieseier BC; Aktas O
    Nervenarzt; 2010 Feb; 81(2):194-202. PubMed ID: 20127230
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Cladribine for multiple sclerosis.
    Drug Ther Bull; 2018 Feb; 56(2):21-24. PubMed ID: 29449328
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.